19 completed. 19 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Phase 2 | 2 | Completed 2 |
Follow Urethral Diseases: new trials by email Literature Review of Urethral Diseases trials Research Report on Urethral Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Pembrolizumab, Docetaxel, Gemcitabine Hydrochloride - Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter, Recurrent Bladder Carcinoma | Phase 1 | Completed | University of California, Davis | 32 | 2015-09-01 | 2022-10-18 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Ramucirumab, Pembrolizumab - Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 | Completed | Eli Lilly and Company | 175 | 2015-07-29 | 2024-07-31 |
| Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Enzalutamide, Cisplatin, Gemcitabine - Bladder Cancer, Carcinoma, Transitional Cell | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 10 | 2015-02-11 | 2019-08-01 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Vinflunine, Sorafenib - Urothelial Carcinoma, Bladder Cancer | Phase 1 | Completed | Dr Anders Ullén | 22 | 2012-05-01 | 2019-04-26 |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors Gemcitabine, Carboplatin, Lenalidomide - Urethral Neoplasms, Neoplasms, Urethral | Phase 1 | Completed | National Cancer Institute (NCI) | 18 | 2011-09-26 | 2026-10-16 |
| A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Cisplatin, Gemcitabine, ALT-801 - Transitional Cell Carcinoma of Bladder, Urethra Cancer | Phase 1 / Phase 2 | Completed | Altor BioScience | 68 | 2011-09-06 | 2024-06-25 |
| EC905 Pharmacokinetic Profile Study Tamsulosin HCl, Solifenacin Succinate, EC905 - Phase 1, Healthy | Phase 1 | Completed | Astellas Pharma Europe B.V. | 46 | 2009-03-01 | 2015-12-18 |
| Two Devices for Reflex Voiding Following Spinal Cord Injury Vibrator, Anal dilator - Spinal Cord Injury, Urinary Incontinence | Phase 1 | Completed | US Department of Veterans Affairs | 3 | 2008-10-01 | 2014-11-05 |
| Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium cisplatin, gemcitabine hydrochloride, temsirolimus - Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 1 / Phase 2 | Completed | Cardiff University | 15 | 2008-02-01 | 2018-02-06 |
| Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Bortezomib, Gemcitabine, Doxorubicin - Solid Tumor, Urethral Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 80 | 2006-09-28 | 2026-10-09 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma ziv-aflibercept - Cancer | Phase 1 | Completed | Regeneron Pharmaceuticals | 25 | 2004-01-01 | 2016-06-03 |
| Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma ziv-aflibercept - Cancer | Phase 1 | Completed | Regeneron Pharmaceuticals | 25 | 2004-01-01 | 2016-06-03 |
| Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium Recombinant Interferon Alfa - Bladder Cancer, Urethral Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2003-12-01 | 2015-05-14 |
| Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions recombinant adenovirus-hIFN-beta - Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 2003-04-01 | 2020-05-13 | |
| Thalidomide and Docetaxel in Treating Patients With Advanced Cancer docetaxel, thalidomide - Cancer | Phase 1 | Completed | Case Comprehensive Cancer Center | 26 | 2002-07-01 | 2010-06-11 |
| MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma entinostat - Cancer | Phase 1 | Completed | National Institutes of Health Clinical Center (CC) | 75 | 2001-03-01 | 2012-03-15 |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer capecitabine, radiation therapy - Cancer | Phase 1 | Completed | Alliance for Clinical Trials in Oncology | 51 | 1999-04-01 | 2016-07-06 |
Urethral Neoplasms (17) · Urinary Bladder Neoplasms (17) · Neoplasms (8) · Carcinoma, Hepatocellular (7) · Carcinoma, Non-Small-Cell Lung (7) · Endometrial Neoplasms (7) · Prostatic Neoplasms (7) · Testicular Neoplasms (7) · Uterine Cervical Neoplasms (7) · Vaginal Neoplasms (7) · Vulvar Neoplasms (7) · Anus Neoplasms (6) · Carcinoma, Ovarian Epithelial (6) · Colonic Neoplasms (6) · Fallopian Tube Neoplasms (6)
Female Urogenital Diseases (19) · Female Urogenital Diseases and Pregnancy Complications (19) · Male Urogenital Diseases (19) · Urogenital Diseases (19) · Urologic Diseases (19) · Neoplasms by Site (17) · Urinary Bladder Diseases (17) · Urogenital Neoplasms (17) · Urologic Neoplasms (17) · Neoplasms by Histologic Type (11) · Neoplasms, Glandular and Epithelial (11) · Carcinoma (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10)
Gemcitabine (6) · Cisplatin (3) · Docetaxel (2) · Trastuzumab (2) · aflibercept (2) · pembrolizumab (2) · ALT-801 (1) · Bortezomib (1) · Capecitabine (1) · Carboplatin (1) · Doxorubicin (1) · Interferon alpha-2 (1) · Interferon-alpha (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Regeneron Pharmaceuticals (2) · Abramson Cancer Center at Penn Medicine (1) · Alliance for Clinical Trials in Oncology (1) · Altor BioScience (1) · Astellas Pharma Europe B.V. (1) · Cardiff University (1) · Case Comprehensive Cancer Center (1) · Dr Anders Ullén (1) · Eli Lilly and Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · National Institutes of Health Clinical Center (CC) (1) · US Department of Veterans Affairs (1) · University of California, Davis (1)
United States (16) · United Kingdom (2) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Spain (1) · Sweden (1)
William P. Tew, MD (2) · Andrea B Apolo, M.D. (1) · Anthony W. Tolcher, MD (1) · Arlene Siefker-Radtke, MD (1) · Ashish M. Kamat, MD (1) · Charles Erlichman, MD (1) · Daniel H. Sterman, MD (1) · James Walter, PhD (1) · Jingsong Zhang, M.D., Ph.D. (1) · John Chester (1) · Primo Lara (1) · Scot C. Remick, MD (1)
PMID 19949018, PMID 22002018, PMID 18470481, PMID 20068553, PMID 29853658, PMID 30552156, PMID 31301962, PMID 33068794
2015 (1), P30CA016672 (1), P30CA043703 (1), P50CA091846 (1), U01CA076576 (1)